p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial

  • Authors:
    • Amir Sonnenblick
    • Roberto Salgado
    • Sylvain Brohée
    • Tamar Zahavi
    • Tamar Peretz
    • Gert Van den Eynden
    • Ghizlane Rouas
    • Asher Salmon
    • Prudence A. Francis
    • Angelo Di Leo
    • John P.A. Crown
    • Giuseppe Viale
    • Laura Daly
    • Bahar Javdan
    • Sho Fujisawa
    • Evandro De Azambuja
    • Ameye Lieveke
    • Martine J. Piccart
    • Jacqueline F. Bromberg
    • Christos Sotiriou
  • View Affiliations

  • Published online on: November 27, 2017     https://doi.org/10.3892/ijo.2017.4212
  • Pages:424-432
Metrics: HTML 0 views | PDF 0 views     Cited By: 0 citations

Abstract

In the present study, in order to investigate the role of signal transducer and activator of transcription 3 (STAT3) in estrogen receptor (ER)-positive breast cancer prognosis, we evaluated the phosphorylated STAT3 (p-STAT3) status and investigated its effect on the outcome in a pooled analysis and in a large prospective adjuvant trial. By using the TCGA repository, we developed gene signatures that reflected the level of p-STAT3. Using pooled analysis of the expression data from luminal breast cancer patients, we assessed the effects of the p-STAT3 expression signature on prognosis. We further validated the p-STAT3 prognostic effect using immunohistochemistry (IHC) and immunofluorescence staining of p-STAT3 tissue microarrays from a large randomised prospective trial. Our analysis demonstrated that p-STAT3 expression was elevated in luminal A-type breast cancer (Kruskal-Wallis test, P<10e-10) and was significantly associated with a good prognosis (log-rank, P<10e-10). Notably, the p-STAT3 expression signature identified patients with a good prognosis irrespective of the luminal subtype (log-rank: luminal A, P=0.026; luminal B, P=0.006). p-STAT3 staining by IHC in the stroma or tumour was detected in 174 out of 610 ER-positive samples (28.5%) from the BIG 2-98 randomised trial. With a median follow-up of 10.1 years, p-STAT3 was associated with a reduced risk of recurrence in ER-positive/HER2-negative breast cancer (Cox univariate HR, 0.66; 95% CI, 0.44-0.98; P=0.04). On the whole, our data indicate that p-STAT3 is associated with an improved outcome in ER-positive breast cancer.

Related Articles

Journal Cover

February 2018
Volume 52 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

2016 Impact Factor: 3.079
Ranked #33/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Sonnenblick, A., Salgado, R., Brohée, S., Zahavi, T., Peretz, T., Van den Eynden, G. ... Sotiriou, C. (2018). p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial. International Journal of Oncology, 52, 424-432. https://doi.org/10.3892/ijo.2017.4212
MLA
Sonnenblick, A., Salgado, R., Brohée, S., Zahavi, T., Peretz, T., Van den Eynden, G., Rouas, G., Salmon, A., Francis, P. A., Di Leo, A., Crown, J. P., Viale, G., Daly, L., Javdan, B., Fujisawa, S., De Azambuja, E., Lieveke, A., Piccart, M. J., Bromberg, J. F., Sotiriou, C."p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial". International Journal of Oncology 52.2 (2018): 424-432.
Chicago
Sonnenblick, A., Salgado, R., Brohée, S., Zahavi, T., Peretz, T., Van den Eynden, G., Rouas, G., Salmon, A., Francis, P. A., Di Leo, A., Crown, J. P., Viale, G., Daly, L., Javdan, B., Fujisawa, S., De Azambuja, E., Lieveke, A., Piccart, M. J., Bromberg, J. F., Sotiriou, C."p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial". International Journal of Oncology 52, no. 2 (2018): 424-432. https://doi.org/10.3892/ijo.2017.4212